FDA GIVES FAST-TRACK STATUS TO SINUNASE

The FDA has granted fast-track status to Accentia Biopharmaceuticals' SinuNase, a product designed to treat chronic sinusitis.

Accentia is preparing to begin a Phase III clinical trial with SinuNase to treat post-surgical patients suffering from recurrent chronic sinusitis. The four-month, double-blind trial will compare patients who are treated with either SinuNase or a placebo, Accentia said.